title: Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats.
abstract: A single oral administration of 1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)cyclohexane]indo l-2 -one SR121463 (0.3-3 mg/kg), a vasopressin non-peptide V(2) receptor antagonist, to rats induced dose-dependent aquaresis which was accompanied by Na(+), K(+), aldosterone and arginine vasopressin excretion over 6 h after dosing. However, no solute excretion was observed over 24 h. As a result of aquaresis, hemoconcentration and increases in plasma angiotensin II and adenocorticotrophin hormone were seen with 3 mg/kg at 2 h after dosing. Chronic treatment with SR121463 (3 mg/kg/dayx28 days) induced a marked aquaresis associated with aldosterone and vasopressin excretion. After a week of treatment, urine volume and aldosterone excretion were reduced ( approximately 40%) and then stabilised, while urine vasopressin excretion remained almost constant throughout the study. There were no changes in arterial pressure, plasma osmolality, plasma sodium concentration, or in number and affinity of liver vasopressin V(1A) and kidney V(2) receptors 24 h after the last treatment. These results indicate that SR121463 is a potent aquaretic agent and might be useful for the chronic management of water-retaining diseases in humans.
authors.affiliation: Cardiovascular Research Department, Sanofi Recherche, 34184, Montpellier, France. colette.lacour@sanofi-synthelabo.com
authors.forename: C
authors.initials: C
authors.lastname: Lacour
authors.forename: G
authors.initials: G
authors.lastname: Galindo
authors.forename: F
authors.initials: F
authors.lastname: Canals
authors.forename: D
authors.initials: D
authors.lastname: Segondy
authors.forename: C
authors.initials: C
authors.lastname: Cazaubon
authors.forename: C
authors.initials: C
authors.lastname: Serradeil-Le Gal
authors.forename: A
authors.initials: A
authors.lastname: Roccon
authors.forename: D
authors.initials: D
authors.lastname: Nisato
mesh_terms: D000284:Administration, Oral; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D004231:Diuresis / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013141:Spiro Compounds / Q000494:pharmacology*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D009025:Morpholines; D013141:Spiro Compounds; D000804:Angiotensin II; D000324:Adrenocorticotropic Hormone; C103281:satavaptan